Medpace CEO Troendle sells $1.59 million of stock

29 Sep 2026, 21:02 by Kim Johansen · The Markets Daily

What happened

Medpace Holdings, Inc. (NASDAQ: MEDP) said President and CEO August J. Troendle, a director and 10% owner, sold 2,564 shares from 2026-09-25 to 2026-09-28. The shares traded at $620.07 to $620.60 each, and the Form 4 puts the total value at about $1.59 million. The filing says the reported price was a weighted average across multiple transactions. It also shows 154 shares sold on 2026-09-25 and 2,410 shares sold on 2026-09-28.

After the first sale, Troendle reported 389,302 shares beneficially owned. After the second, he reported 386,892. The filing also shows 4,733,019 shares held indirectly through Medpace Investors, LLC. Troendle is also listed as the sole manager and controlling unit holder of Medpace Investors, LLC.

Key numbers

Metric	Latest	Source
Shares sold	2,564 shares	SEC Form 4
Sale price range	$620.07 to $620.60 per share	SEC Form 4
Total sale value	about $1.59 million	SEC Form 4
Shares held after	386,892 shares	SEC Form 4
Indirect shares held	4,733,019 shares	SEC Form 4

Why it matters

OptimistFi's case is that Medpace works if its focused CRO model keeps winning outsourced clinical-development work while preserving unusually strong margins and cash conversion. This Form 4 is about ownership, not operations, but it does put a recent insider sale in that context. By OptimistFi's calculation, the 2,564 shares were about 0.7% of the 389,456-share pre-trade holding. That is a small slice of the stake, and the post-trade position is still large.

The filing says the trades were made pursuant to a limit order placed during an open window period. Troendle's indirect Medpace Investors, LLC holdings also remain on the filing, so his overall exposure is still material. The trade matters more as an ownership update than as a read on the business itself. It does not change the operating case.

Browse: stock research on every company OptimistFi covers

What's next

The next quarterly report will be the first operating update after this filing. That report is the next test of whether Medpace is still delivering the operating results behind the case. A report that keeps margins and cash conversion strong would support OptimistFi's view. A weaker report would weaken it. Until then, this Form 4 is mainly a dated ownership snapshot that investors can compare with the next report.

Sources

SEC Form 4 — Troendle reported sales of Medpace Holdings, Inc. common stock and post-trade holdings.

Read the full OptimistFi thesis on Medpace Holdings, Inc.: https://optimistfi.com/stocks/MEDP

See what would break the Medpace Holdings, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

The full Medpace Holdings, Inc. investment case, its status and the next test to watch live on the Medpace Holdings, Inc. thesis page.